Results 281 to 290 of about 231,349 (305)
Some of the next articles are maybe not open access.
Checkpoint inhibitors in pancreatic cancer
Cancer Treatment Reviews, 2019Immune checkpoint inhibitors, targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and the programmed cell death protein-1 (PD-1)/programmed cell death ligand-1 (PD-L1) pathways have shown remarkable potential in several types of cancer. In this review we summarize published and ongoing studies on checkpoint inhibitors in pancreatic cancer ...
Andreas Henriksen +3 more
openaire +2 more sources
Checkpoint inhibitors go viral
Nature Biotechnology, 2019As clinical evidence mounts demonstrating the power of combining oncolytic viruses and checkpoint inhibitors, companies are scrambling to get in on the action.
openaire +2 more sources
Cardiotoxicity of Immune Checkpoint Inhibitors
Current Treatment Options in Cardiovascular Medicine, 2019Immunotherapies, particularly immune checkpoint inhibitors (ICI), are revolutionary cancer therapies being increasingly applied to a broader range of cancers. Our understanding of the mechanism, epidemiology, diagnosis, and treatment of cardiotoxicity related to immunotherapies remains limited.
Lili, Zhang +8 more
openaire +2 more sources
Checkpoint Inhibitor–Induced Colitis
American Journal of Gastroenterology, 2020Immune checkpoint inhibitors have revolutionized treatment and overall survival for several different types of cancer. Antibodies to cytotoxic T-lymphocyte-associated protein 4 and to programmed cell death protein 1 and its ligand enhance cytotoxic T-cell survival, thus augmenting antitumor action and consequently inducing immune-related adverse events,
Emanuelle, Bellaguarda, Stephen, Hanauer
openaire +2 more sources
Immune checkpoint inhibitor myocarditis
Current Opinion in Cardiology, 2019The purpose of this study is to summarize and highlight the recent literature regarding immune checkpoint inhibitor myocarditis.The use of immune checkpoint inhibitors, a promising form of immunotherapy, is rapidly increasing in oncology. These drugs have been recently found to cause a fulminant myocarditis associated with a high-case fatality rate ...
Jayant, Raikhelkar, Nir, Uriel
openaire +2 more sources
Melanoma and Immune Checkpoint Inhibitors
Current Oncology Reports, 2018Prognosis of patients with advanced melanoma is dismal with a median overall survival of about 8Â months and 5-year overall survival from a diagnosis of metastatic disease of roughly 10%. However, immune checkpoint inhibitors have brought indispensable benefits to melanoma patients.
Masutaka, Furue +5 more
openaire +2 more sources
Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies
Nature Reviews Drug Discovery, 2021Ryan J Sullivan +2 more
exaly